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REVIEW AND COMPARISON OF DIFFERENT NATIONAL GUIDELINES ON THE
IMPLEMENTATION OF NETWORK META-ANALYSIS
Hawkins N1, Laws AJ2, Kendall RM2
1Oxford Outcomes, Oxford, UK, 2Oxford Outcomes, Vancouver, BC, Canada
OBJECTIVES: For an evaluation of a treatment to be truly useful, it should be com-
pared to the other treatments that may be used in the patient group under consid-
eration. Randomised controlled trials are a key source of evidence for these com-
parisons. The techniques of indirect comparisons and network meta-analysis
allow the complete network of trial evidence to be evaluated in order to obtain
estimates of comparative efficacy. These techniques may be the only source of
estimates of comparative effectiveness if trials directly comparing the treatments
of interest have not been conducted andmay provide useful additional evidence if
both direct and indirect comparisons exist. METHODS: We examined both pub-
lished and draft guidelines from reimbursement and health technology appraisal
bodies, and considered their recommendations using appropriatemethodology for
the conduct of indirect comparisons and the assessments of their validity.
RESULTS: The following countries were studied; Australia, Canada, France, Ger-
many, Korea, Sweden, and USA, with particular emphasis on the differences and
similarities in these guidelines with each other, and with the guidelines estab-
lished by the Cochrane collaboration. CONCLUSIONS: Finally, we present an ex-
ample analysis demonstrating how the various requirements could bemet in prac-
tice.
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GLOBAL EVIDENCE GENERATION - CHALLENGES FOR THE PHARMA INDUSTRY
Mukku S
Double Helix Consulting Group, London, UK
Health technology assessments around the world are changing at a pace that it is
becoming extremely difficult for the pharmaceutical companies to keep up to the
demands of health authorities around the world. Market access, commercial and
more specifically clinical development teams are facing a mamoth task of devel-
oping and generating clinical data in a form that will satisfy the increasing expec-
tations of health care systems around the world. OBJECTIVES: This research paper
analysis the current trends in data expectations from key markets around the
world. This specific objective was to develop a matrix that will identify the differ-
ences and commonalities in clinical data expectations in selected key markets of
US, France, Germany, UK, The Netherlands, Spain, Italy, Poland, China, Australia,
Turkey, India, Brazil and Mexico. METHODS: A combination of ndepth secondary
research followed by interviews with key stakeholders in eachmarket was used to
achieve the objectives of the project. Clinical experts who are involved in clinical
trial design in key research centres, payers at the national and regional level and
executives from pharmaceutical industry were interviewed. RESULTS: It was con-
cluded that there is huge variance in data expectations in the selectedmarkets and
for this reason countries could be placed in different buckets. For instance, some
countries focus on economic assessment (UK, Australia) while other focus on well
designed RCTs against relevant comparator (Germany, France). The 2011 introduc-
tion of AMNOG has resulted in deadlock between the manufacturers and the GBA
(Joint federal committee) in Germany on the choice of comparator. Similarly the
new clinical guidelines that are being introduced in China require data with local/
Chinese population. The French Transparency (TC) commission is not considering
drugs as valuable (AMSR scoring) if they are not supported with a well designed
comparator study. The paper elaborates on such global challenges.
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INVESTMENT AND DISINVESTMENT OF HEALTH TECHNOLOGIES: THE NEED
FOR TWO COST-EFFECTIVENESS THRESHOLDS
Paulden M
University of Toronto, Toronto, ON, Canada
OBJECTIVES: The concept of a cost-effectiveness “threshold” has been adopted
either explicitly or implicitly by health care decision makers in numerous jurisdic-
tions. This paper demonstrates that, under very weak assumptions – applicable to
all realworld health systems – decision makers ought to instead adopt two cost-
effectiveness thresholds.METHODS: A simple model of a hypothetical health care
system is used to demonstrate the appropriate threshold(s) under various assump-
tions concerning: 1) the size of the health care budget; 2) the extent to which
technology, productivity and/or input prices change over time; 3) whether the
amount of information available to decision makers changes over time; and 4) the
fixity of the set of adopted health care technologies in the short term. RESULTS:
The assumptions whichmust hold for two thresholds to be appropriate are that: 1)
there is some fixity in the set of adopted health care technologies in the short term,
and 2) either 1) technology, productivity and/or input prices change over time, or 2)
the information available to decision makers changes over time, or both. Where
these assumptions hold, one threshold ought to be used when appraising technol-
ogies with positive incremental costs (investment decisions), while a different
threshold should be usedwhen appraising technologies with negative incremental
costs (disinvestment decisions). This is true regardless of the marginality of the
technologies under consideration. CONCLUSIONS: This finding has profound im-
plications for the practice of cost-effectiveness analysis, for ongoing and future
empirical research into the nature of the threshold, and for health care policy
making. It gives a theoretical underpinning to observations that the ICERs of tech-
nologies disinvested at themargin differ from those of technologies adopted at the
margin. It also has implications for the interpretation of ICERs, for the appropriate
calculation of net benefit, and for the conduct of value of information analysis.
DISEASE-SPECIFIC STUDIES
MUSCULAR-SKELETAL DISORDERS – Clinical Outcomes Studies
PMS1
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF DULOXETINE PATIENTS
WITH CHRONIC LOWER BACK PAIN OR OSTEOARTHRITIS IN 2011
Able SL1, Preston H2, Victor H2
1Eli Lilly and Company, Inc., Indianapolis, IN, USA, 2IMS Health Consulting Group, Plymouth
Meeting, PA, USA
OBJECTIVES: Identify and compare demographic and clinical characteristics of
patients diagnosed with osteoarthritis (OA) or chronic lower back pain (CLBP) who
initiated treatment on duloxetine after FDA approval of its use for management of
chronic musculoskeletal pain late in 2010. METHODS: Commercial patients 18-64
years of age who initiated duloxetine treatment between January 1, 2011 and July
30, 2011 were identified in the IMS Longitudinal Prescription and Medical Claims
Database. The index event was defined as the first duloxetine prescription fill with
no duloxetine pill-coverage for 90 days prior. Patients were assigned to disease-
category cohorts on the basis of ICD-9 codes on medical claims dated within
-180/7 days of the index event. 2-tests were used to compare differences across
study cohorts. Additional cohorts based on other FDA approved duloxetine indica-
tions and for the same time period a year prior to the primary study period were
constructed for comparison. RESULTS: A total of 422,911 duloxetine initiators with
1 of duloxetine’s six approved indications were identified in the IMS database, of
which 80,637 had either CLBP (42,280) or OA (38,357) as the only diagnosed condi-
tion from among the six. OA patients were older than CLBP patients (60.6 vs. 52.1
years; p0.001). An almost equal proportion of OA and CLBP patients (47%) were
treated by primary care physicians. CLBP patients were more likely prescribed an
anticonvulsant (52.7% vs 37.3%; p0.001) or an opioid (93.5% vs. 84.1%; p.001) than
were OA patients. OA patients weremore likely to have been previously diagnosed
with a non-CLBP related musculoskeletal pain condition. OA patients were more
likely to initiate duloxetine treatment at sub-therapeutic (40 mg/day) dosing lev-
els than CLBP patients (32.1% vs. 26.8%; p0.001). Results for 2011 were little
changed from 2010 results. CONCLUSIONS: Overall, patient profiles among dulox-
etine initiatorswith CLBP displayedmodest differentiation relative to patientswith
OA in 2011.
PMS2
THE EFFICACY OF DULOXETINE, NON-STEROIDAL ANTI-INFLAMMATORY
DRUGS, AND OPIOIDS IN OSTEOARTHRITIS: A META-ANALYSIS
Myers JA1, Wielage RC1, Han B2, Price K2, Gahn JC1, Paget MA3, Happich M4
1Medical Decision Modeling Inc., Indianapolis, IN, USA, 2Eli Lilly and Company, Inc., Indianapolis,
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OBJECTIVES: Comparative evidence evaluating the efficacy of oral osteoarthritis
treatments has frequently included short-term trials. Meta-analyses of longer-
term trials are needed. This meta-analysis of trials 12 weeks or longer was con-
ducted to assess the efficacy of duloxetine vs. other oral treatments recommended
after the use of acetaminophen for osteoarthritis, including non-steroidal anti-
inflammatory drugs (NSAIDs) and opioids. METHODS: Search strategy: A system-
atic literature review was performed in PUBMED, EMBASE, MedLine In-Process,
Cochrane Library, and ClinicalTrials.gov up to September 2011. Randomized con-
trolled trials (RCTs) of duloxetine and all oral NSAIDs and opioids were included if
the duration of treatment was twelve weeks or longer, the Western Ontario and
McMaster Universities Index (WOMAC) total score was available, and they were
published in English. Data collection and analysis: The WOMAC baseline and
change from baseline total scores were collected and standardized. Twelve addi-
tional study characteristics were collected and study quality was assessed. A fre-
quentist meta-analysis and indirect comparison were performed using the DerSi-
monian-Laird and Bucher methods. Bayesian analyses with and without study-
level covariates were performed using noninformative priors. RESULTS: A search
of the literature identified 24 studies which met inclusion criteria. The frequentist
analysis and the Bayesian analysis without covariates found no statistically signif-
icant difference between the efficacy of duloxetine and the other treatments.Meta-
regression suggested baseline scores explain much of the variance in change from
baseline scores. The results, however, adjusted for study-level covariates led to the
same conclusion. CONCLUSIONS: This analysis suggests that the efficacy of dulox-
etine in osteoarthritis, as measured by the WOMAC total score at 12 weeks or
longer, is similar to competitor drugs.
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COMPARATIVE EFFECTIVENESS ANALYSIS USING “REAL-WORLD” PATIENT
DATABASE TO EVALUATE THE FRACTURES RATES COMPARING ANNUAL
ZOLEDRONIC ACID INFUSION WITH ORAL BISPHOSPHONATES
Lian J1, Song X2, Varker H2, Cao Z2, Recknor C3
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Thomson Reuters, Cambridge,
MA, USA, 3United Osteoporosis Centers, Gainesville, GA, USA
OBJECTIVES: This study evaluated clinical fracture rates before and after two years
of zoledronic acid infusion (ZOL) or oral bisphosphonate (OBP) initiation using a
large national claims data set. METHODS: Patients 45 years with at least one
claim of ZOL or OBP were extracted from Thomson Reuters MarketScan® Data-
bases January 1, 2006-October 31, 2010. Index date was the date of the first ZOL or
OBP claim. Each patient had 1 diagnosis of osteoporosis prior to index date. All
patients had at least two-year continuous enrollment prior to (pre-period) and
two-year continuous enrollment post (follow-up period) index date. Patients with
any ZOL use during the study period were excluded from the OBP cohort. Differ-
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